PVigi

TİTCK Pharmacovigilance System Guideline

English translation of the guideline describing TİTCK's own pharmacovigilance system: TÜFAM's structure, tasks, processes and quality system.

Published: 2022-11-15 · Source: TİTCK

This text is provided for reference. The official version is published by the Turkish Medicines and Medical Devices Agency (TİTCK).

1.1. Purpose

The purpose of this Guideline is to describe the structure of the pharmacovigilance system established within the Turkish Medicines and Medical Devices Agency.

This Guideline has been prepared on the basis of the Pharmaceutical and Medicinal Preparations Law No. 1262 of 14/5/1928; sub-paragraph (k) of the first paragraph of Article 3 of the Basic Law on Health Services No. 3359 of 7/5/1987; Articles 508 and 796 of Presidential Decree No. 4 on the Organisation of Institutions and Organisations Affiliated, Related and Associated with Ministries and Other Institutions and Organisations; the "Regulation on the Safety of Medicinal Products"; and the Directive on the Duties of the Departments Attached to the Service Units of the Turkish Medicines and Medical Devices Agency.

1.3. Definitions

For the purposes of this Guideline:

  • a) Adverse reaction / suspected adverse reaction: a response to a medicine which is noxious and unintended,
  • b) Ministry: the Ministry of Health,
  • c) Medicinal product for human use (medicine): any substance or combination of substances 1) presented as having properties for treating or preventing disease in human beings, or 2) used in or administered to human beings with a view to restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action, or to making a medical diagnosis,
  • d) Serious adverse reaction: an adverse reaction that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a congenital anomaly/birth defect,
  • e) Pharmacovigilance: the activities and scientific work relating to the detection, assessment, understanding and prevention of adverse reactions and other medicine-related problems,
  • f) Provincial pharmacovigilance officer: the relevant head or deputy head of the provincial health directorate responsible for coordinating and training the pharmacovigilance contact points in the province and for overseeing their work,
  • g) Pharmacovigilance contact point: the physician or pharmacist (or, where neither is available, the dentist) responsible in the healthcare institution where they work for encouraging adverse reaction reporting, carrying out training and information activities and forwarding the adverse reaction reports they receive to TÜFAM,
  • h) Pharmacovigilance system: the system used by marketing authorisation holders and applicants, the Agency and other organisations to fulfil the tasks and responsibilities set out in the Regulation on the Safety of Medicinal Products, designed to monitor the safety of medicines and detect any change in their benefit-risk balance,
  • i) Pharmaceutical Track and Trace System (İTS): the central registration and tracking system that serialises medicinal products for human use using a QR/data-matrix code, monitors in real time all movements in the supply chain such as production, import, export, purchase, sale, transfer, consumption, wastage and reimbursement (and their cancellation) through notifications from every point each unit passes, and in which actions such as recall and blocking of these products are performed,
  • j) Agency: the Turkish Medicines and Medical Devices Agency (TİTCK),
  • k) MedDRA: the Medical Dictionary for Regulatory Activities developed by the International Council for Harmonisation,
  • l) Healthcare professional (HCP): in the context of reporting suspected adverse reactions, physicians, pharmacists, dentists, nurses and midwives,
  • m) Signal: information arising from one or multiple sources, including observations and experiments, which suggests a new potentially causal association, or a new aspect of a known association, between an intervention and an event or set of related events, either adverse or beneficial, that is judged to be of sufficient likelihood to justify verificatory action,
  • n) Consumer: in the context of reporting suspected adverse reactions, a person who is not a healthcare professional, such as a patient or a patient's lawyer, friend or relative/parent/child,
  • o) VigiFlow: the web-based platform that enables suspected adverse reactions to be shared securely, in a controlled way and easily with the WHO through its global database VigiBase, with the EMA (EudraVigilance) or with other systems such as DHIS2 and Vigilance Hub,
  • p) VigiLyze: a signal detection and signal management tool used by members of the WHO Programme for International Drug Monitoring as a starting point for quantitative signal detection.

Section II – Structures and Processes

2.1. Mission and organisational structure of the Agency

The Agency's mission is to serve society through regulatory, supervisory and guiding activities concerning medicines, medical devices, traditional herbal products, food supplements, advanced therapy medicinal products and cosmetic products.

The Agency's organisational structure is shown in Figure 1.

*(Figure 1. Organisational structure of TİTCK – see the PDF published by TİTCK for the chart.)*

2.2. The Agency's pharmacovigilance system

The requirements for carrying out the tasks that make up the Agency's pharmacovigilance system are set out in detail in standard operating procedures, guidelines and guidance documents that form part of the integrated quality management system.

The pharmacovigilance system is integrated into the Agency's overall quality system and takes into account the core values set out in the Agency's strategic plan, such as scientific rigour, independence, competence, transparency, impartiality, consistency, reliability, openness to development and innovation, and respect for people.

2.2.1. Documentation

This guideline documenting the Agency's pharmacovigilance system is reviewed at least once a year by the Department of Pharmacovigilance and Controlled Substances. When it is updated, the following are taken into account:

  • Changes in pharmacovigilance legislation that create new pharmacovigilance tasks or restructure existing ones
  • Changes in other legislation relevant to pharmacovigilance
  • Scientific and technical developments
  • Relevant organisational changes leading to changes in responsibilities

2.2.2. Definition and characteristics

The Agency's pharmacovigilance system is the system used to fulfil the Agency's legal pharmacovigilance tasks and responsibilities, designed to monitor the safety of medicinal products for human use authorised by the Agency and to detect changes in their benefit-risk balance. The characteristics of the pharmacovigilance system are defined by its structures, resources, processes, tools, outputs and outcomes.

The Agency's quality system cycle is based on the following four actions:

  • Quality planning: establishing structures and planning integrated and consistent processes
  • Quality adherence: carrying out tasks and responsibilities in accordance with quality requirements
  • Quality control and assurance: monitoring and evaluating how effectively structures have been established and how effectively processes are carried out
  • Quality improvements: correcting and improving structures and processes where necessary

2.2.3. Data and record management

All data, documents and records relating to the Agency's pharmacovigilance system are stored in designated physical and electronic folders and databases and are kept in accordance with the relevant legislation and the requirements of the TİTCK quality management system on data and record management.

2.2.4. The Agency's pharmacovigilance tasks

The definition of a medicinal product for human use also covers vaccines, and the Agency's pharmacovigilance tasks are carried out in line with the "Regulation on the Safety of Medicinal Products", the current "Adverse Events Following Immunisation (AEFI) Circular" of the General Directorate of Public Health and Circular No. 2022/2 of 28.09.2022.

2.2.4.1. Department of Pharmacovigilance and Controlled Substances

The Agency's pharmacovigilance system is run by the Department of Pharmacovigilance and Controlled Substances, whose main tasks are:

  • a. Running a pharmacovigilance system that meets the requirements of the quality system
  • b. Preparing pharmacovigilance legislation
  • c. Collecting and managing adverse drug reactions
  • d. Sending adverse drug reactions to the database of the World Health Organization Uppsala Monitoring Centre (WHO-UMC)
  • e. Reviewing periodic benefit-risk evaluation reports
  • f. Reviewing risk management plans
  • g. Signal management
  • h. Managing emerging safety issues
  • i. Managing the list of products subject to additional monitoring
  • j. Taking risk minimisation measures and monitoring their effectiveness
  • k. Safety communication
  • l. Post-authorisation safety studies
  • m. Monitoring the compliance of marketing authorisation holders
  • n. Providing the best evidence to support regulatory decision-making

2.2.4.2. Vice-Presidency for Inspection Services

  • a. Pharmacovigilance inspections: carried out by the Agency's inspectors.

2.2.4.2.1. Department of Medicines Inspection

  • a. Planning pharmacovigilance inspections
  • b. Communicating the inspection report outcome to the company
  • c. Taking action on the opinions stated in the inspection report
  • d. Forwarding correspondence between the inspector and the company to the parties
  • e. Where an adverse reaction report is thought to be related to a quality defect, taking samples from the market and sending them to the Analysis and Control Laboratories
  • f. Where deemed necessary, blocking sales and carrying out recalls in İTS

2.2.4.3. Processes covering pharmacovigilance throughout the life cycle of a medicinal product

Pharmacovigilance work is organised into five process groups covering pharmacovigilance throughout the life cycle of the medicinal product (see Table 1):

  • 1. Collect, manage and analyse: this process group describes the collection, overall management and, where appropriate, analysis of data, information and documents on product safety.
  • 2. Review and assess: this process group describes the overall review and analysis of data, information and documents on product safety (e.g. by committee members).
  • 3. Decide and act: this process group describes the overall coordination of decision-making through the scientific committees.
  • 4. Communicate: this process group describes the overall coordination of safety communication.
  • 5. Monitor: this process group describes the overall monitoring of the implementation and impact of the recommended regulatory actions.

Responsibilities per process area for pharmacovigilance (throughout the product life cycle):

The Agency's pharmacovigilance tasksCollect, manage, analyseReview and assessDecide and actCommunicateMonitor
Running the pharmacovigilance systemTÜFAM/PRMUTÜFAM/PRMUTÜFAM/PRMUTÜFAM/PRMUTÜFAM/PRMU
Adverse reaction managementTÜFAMTÜFAMTÜFAMTÜFAMTÜFAM
Periodic benefit-risk evaluation reportsPRMUPRMUPRMUPRMUPRMU
Risk management plansPRMUPRMUPRMUPRMUPRMU
Signal managementTÜFAMTÜFAMTÜFAMTÜFAMTÜFAM
Emerging safety issuesTÜFAM/PRMUTÜFAM/PRMUPRMUPRMUPRMU
Managing the list of products under additional monitoringPRMUPRMUPRMUPRMUPRMU
Risk minimisation measures and effectiveness monitoringPRMUPRMUPRMUPRMUPRMU
Safety communicationTÜFAM/PRMUTÜFAM/PRMUPRMUPRMUPRMU
Post-authorisation safety studiesPRMUPRMUPRMUPRMUPRMU
Providing the best evidence to support regulatory decision-makingTÜFAM/PRMUTÜFAM/PRMUTÜFAM/PRMUTÜFAM/PRMUTÜFAM/PRMU

Table 1. Sharing of responsibilities between TÜFAM and the Pharmacovigilance Risk Management Unit (PRMU)

2.2.5. Distribution of pharmacovigilance tasks between units

Pharmacovigilance activities within the Department of Pharmacovigilance and Controlled Substances are carried out in two sections: the Turkish Pharmacovigilance Centre (TÜFAM) and the Pharmacovigilance Risk Management Unit. The relationship of the Department with other departments in carrying out its pharmacovigilance tasks is described in detail in the "TİTCK Vice-Presidency for Medicines and Pharmacy Internal Communication Guideline".

2.2.5.1. Tasks of TÜFAM

  • a) Collecting adverse reactions to medicines occurring in Türkiye (i. AEFI reports for vaccines administered under the Expanded Programme on Immunisation (EPI) are collected and followed up by the General Directorate of Public Health (see the current "Adverse Events Following Immunisation Circular"); these reports are forwarded to TÜFAM in line with Circular No. 2022/2. ii. For vaccines not covered by the EPI, reports are sent to TÜFAM directly by HCPs, consumers and marketing authorisation holders.)
  • b) Reviewing adverse reaction reports for completeness and consistency and taking the necessary action
  • c) Acknowledging receipt of adverse reaction reports and giving feedback where necessary
  • d) Preparing adverse reaction data for analysis according to defined standards, coding them in MedDRA and entering them in the database
  • e) Sending adverse reaction reports to the database of the WHO Uppsala Monitoring Centre
  • f) Performing signal analysis and handling the work related to signals that arise
  • g) Forwarding reports of suspected serious adverse reactions received directly by TÜFAM to the marketing authorisation holder within fifteen days of receipt
  • h) Taking the measures needed to encourage spontaneous reporting by HCPs and consumers so that the pharmacovigilance system works as well as possible
  • i) Organising basic pharmacovigilance training programmes
  • j) Ensuring communication and coordination with pharmacovigilance contact points
  • k) Preparing legislation in its area of responsibility

2.2.5.1.1. Sources of adverse reaction reports

The sources of adverse drug reaction reports are:

  • a) Healthcare professionals: HCPs can report directly to TÜFAM through the electronic reporting system, e-mail, post, fax or telephone. They can also report directly to TÜFAM through the pharmacovigilance contact point at the hospital where they work.
  • b) Consumers: consumers can report directly to TÜFAM through a free telephone line, the electronic reporting system, e-mail, post or fax. In addition, when consumers mention an adverse drug reaction in an application to the Ministry of Health Communication Centre (SABİM) or the Presidential Communication Centre (CİMER), the application is forwarded to TÜFAM.
  • c) Pharmacovigilance contact points: their working principles are described in the Standard Operating Procedure on Pharmacovigilance Contact Points. Contact points can report to TÜFAM by official letter through the Electronic Application and Process Management (ESY) system, the electronic reporting system, e-mail, post or fax.
  • d) Marketing authorisation holders: MAHs are obliged to report to TÜFAM within 15 days the serious adverse reaction reports they receive from healthcare professionals or consumers, and case reports of serious adverse reactions identified through literature screening. Reports are sent to TÜFAM by official letter through the ESY system. The content, format and submission of reports are described in detail in GVP Module I – Management and Reporting of Adverse Drug Reactions.
  • e) General Directorate of Public Health: follow-up of AEFIs related to vaccines used in the Expanded Programme on Immunisation is carried out by the Department of Vaccine-Preventable Diseases. AEFI reports are notified to TÜFAM by that Department in accordance with the procedures set out in Circular No. 2022/2. The sources of adverse reaction reports are shown in Figure 2.

*(Figure 2. Data flow – see the PDF published by TİTCK for the chart.)*

2.2.5.2. Pharmacovigilance Risk Management Unit

  • a) Following warnings on medicine safety published by competent authorities that are founding or standing members of the ICH (International Council for Harmonisation), the Australian Therapeutic Goods Administration (TGA), the UK MHRA or the WHO Uppsala Monitoring Centre, and taking the necessary measures to minimise risk for medicines authorised or under application in Türkiye in line with those warnings
  • b) Reviewing periodic benefit-risk evaluation reports when marketing authorisations are renewed
  • c) Reviewing the risk management plans (RMPs) that applicants must submit under the Regulation on the Safety of Medicinal Products
  • d) Preparing the list of medicines subject to additional monitoring, taking international practice into account, updating it at least twice a year and publishing it on the Agency's website
  • e) Reviewing RMP updates that require additional pharmacovigilance or additional risk minimisation activities, or changes to existing activities
  • f) After the reviews and assessments, taking one or more of the following measures to ensure the safe use of the medicine
  • g) Ensuring changes to the safety sections of the SmPC/PL (such as adding a new contraindication, reducing the dose or restricting the indication) (dose changes, including restriction of the indication or dose reduction, together with the Department of Marketing Authorisation)
  • h) Ensuring that a warning is placed on the immediate or outer packaging
  • i) Requiring a post-authorisation safety study (together with the Department of Marketing Authorisation)
  • j) Ensuring suspension or revocation of the marketing authorisation (together with the Department of Marketing Authorisation)
  • k) Refusing renewal of the marketing authorisation (together with the Department of Marketing Authorisation)
  • l) Requiring an information letter to inform healthcare professionals of new safety information on the medicine (letters on quality or supply problems are not within the remit of the Department of Pharmacovigilance and Controlled Substances)
  • m) Informing the marketing authorisation holder and relevant international organisations of the measures taken as a result of pharmacovigilance work
  • n) Requesting certain obligations from healthcare professionals to be applied in their routine clinical work (such as the "Drug Safety Monitoring Form" practice)
  • o) Keeping records of qualified persons for pharmacovigilance and their deputies
  • p) Preparing legislation in its area of responsibility

2.2.6. Pharmacovigilance Committee

Under the "Regulation on the Establishment and Duties of the Scientific Advisory Committees of the Turkish Medicines and Medical Devices Agency" and the "Procedures and Principles on Payments to Members of Scientific and Marketing Authorisation Committees Established by the Ministry of Health", 25 experts from different specialties are appointed to the Pharmacovigilance Committee with the Minister's approval. All members are faculty members working in university hospitals. Depending on the agenda, 10 of these members are invited to the committee, which meets every fifteen days. Meetings may be held more often if needed.

The Pharmacovigilance Committee was established to assess medicine safety issues and to carry out causality assessment of serious adverse reaction reports.

Committee members' declarations of conflicts of interest, declarations and undertakings, and ethics agreements are managed in accordance with the requirements of the integrated quality management system. Members must complete, sign and submit these documents to the Agency before taking up their duties.

2.3. Stakeholders of the pharmacovigilance system and communication topics

2.3.1. Internal stakeholders

Communication with internal stakeholders is described in detail in the TİTCK Vice-Presidency for Medicines and Pharmacy Internal Communication Guideline. Only the main communication topics are listed here.

  • a) Department of Marketing Authorisation – main communication topics: assessment of SmPC/PL and packaging applications; obtaining additional opinions and assessments where needed; pharmacovigilance data submitted with marketing authorisation applications and renewals; authorisation, suspension, revocation and refusal of renewal of marketing authorisations.
  • b) Department of Clinical Trials – main communication topics: post-authorisation safety studies; safety issues arising during clinical trials.
  • c) Department of Herbal and Supplement Products – main communication topics: side-effect reports for foods for special medical purposes; pharmacovigilance data submitted when authorisations of traditional herbal medicinal products are renewed.
  • d) Department of Medicines Inspection – main communication topics: adverse reaction reports raising suspicion of a quality defect; sales blocking and recalls.
  • e) Agency inspectors – main communication topics: pharmacovigilance inspections.
  • f) Department of Analysis and Control Laboratories – main communication topics: information sharing under the batch release guideline.

2.3.2. Stakeholders within the Ministry of Health

  • a) General Directorate of Public Hospitals – main communication topics: healthcare professionals working in healthcare facilities, including Oral and Dental Health Centres; pharmacovigilance contact points; patients and relatives receiving services from healthcare facilities, including Oral and Dental Health Centres; Pharmacovigilance Committee members.
  • b) General Directorate of Public Health – main communication topics: Department of Family Medicine (family physicians and family health staff working in Family Health Centres, and patients receiving services from them); Department of Vaccine-Preventable Diseases (running the Expanded Programme on Immunisation and following up AEFIs occurring under it); Department of Tuberculosis (healthcare professionals working in tuberculosis dispensaries and their patients); Department of Zoonotic and Vector-Borne Diseases (healthcare professionals who procure and distribute vaccines, antisera and medicines for controlling these diseases, and the patients who use them); National Poison Information Centre (healthcare professionals who detect adverse reactions during poisoning reports, and the patients concerned).
  • c) General Directorate of Health for Borders and Coastal Areas – main communication topics: healthcare professionals administering travel vaccines and prophylactic medicines in travel health centres, and the patients receiving them.
  • d) Provincial Health Directorates – main communication topics: provincial pharmacovigilance officers.

2.3.3. Stakeholders outside the Ministry of Health

  • a) Pharmaceutical companies and the non-governmental organisations they belong to – main communication topics: all stages of carrying out pharmacovigilance activities.
  • b) Universities – main communication topics: Pharmacovigilance Committee members; healthcare professionals working in healthcare facilities; pharmacovigilance contact points; patients and relatives receiving services from healthcare facilities.
  • c) Healthcare professionals – main communication topics: adverse reaction reports; safety warnings.
  • d) Public professional bodies (Turkish Medical Association, Turkish Pharmacists' Association, chambers of pharmacists) – main communication topics: direct healthcare professional communications (DHPC).
  • e) Patients and patient associations – main communication topics: adverse reaction reports; safety warnings.
  • f) Medicines authorities of other countries – main communication topics: medicine safety warnings; information sharing.
  • g) WHO-UMC – main communication topics: adverse reactions; signal analysis; international cooperation.
  • h) Media – main communication topics: news on medicine safety; press releases; media campaigns for pharmacovigilance.

3. Human resources management

3.1. Recruitment and training of staff

In line with the relevant Turkish legislation and the requirements of the Agency's integrated quality management system, all Agency staff are recruited on the basis of adequate qualifications and experience. All new and existing staff receive initial and continuous training on their roles and responsibilities.

At least once a year, the Department of Pharmacovigilance and Controlled Substances assesses the training needs for pharmacovigilance tasks, taking into account scientific progress and the development of new pharmacovigilance concepts. Training plans are drawn up for this purpose and monitored regularly.

3.2. Job descriptions

Individual roles and responsibilities are documented in job descriptions that are kept up to date.

4. Systems supporting the Agency's pharmacovigilance system

  • Electronic Application and Process Management System (EBS-ESY): this system allows records to be kept electronically and documents to be retrieved easily.
  • Pharmaceutical Track and Trace System (İTS): thanks to data-matrix technology, İTS makes it possible to track every movement of medicinal products for human use in the supply chain from production or import onwards. Each product is serialised with the code printed on every pack, and every location, time and status from its entry into the supply chain is recorded in the database. As a result, when a medicine causes an adverse reaction in a healthcare facility, it is possible to identify which other facilities hold the same medicine, and barcode/batch-based recalls or blocks can be carried out without delay.
  • VigiFlow: this platform, which sends adverse reactions to the WHO database VigiBase, has been used by TÜFAM under a licence since 2005. Only authorised TÜFAM users can enter data.
  • VigiLyze: VigiLyze allows signals arising in Türkiye to be followed and gives access to all reports in the WHO database.

5. Monitoring of the Agency's pharmacovigilance system

The Agency monitors the performance of its pharmacovigilance system every three months using the performance indicators in its strategic plan. The indicators monitored are:

  • The number of adverse reaction reports per million population
  • The number of training sessions given to HCPs

The aim is to achieve an increase in the indicators measured under the "Guideline on Pharmacovigilance Indicators" published on 23.08.2022.

5.1. Internal audit

Risk-based system audits are carried out by the Agency's Internal Audit Unit.

More guidelines